Viridian Therapeutics Q2 EPS $(1.27) Beats $(1.29) Estimate, Sales $72.00K Miss $220.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Viridian Therapeutics reported Q2 losses of $(1.27) per share, beating the analyst consensus estimate of $(1.29) by 1.55 percent. However, this is a 19.81 percent decrease over losses from the same period last year. The company's quarterly sales of $72.00 thousand missed the analyst consensus estimate of $220.00 thousand by 67.27 percent, marking a 71.88 percent decrease over sales from the same period last year.

August 08, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viridian Therapeutics' Q2 earnings beat estimates but sales significantly missed expectations. This could potentially impact the company's stock negatively in the short term.
While Viridian Therapeutics beat earnings estimates, the significant miss on sales could be a concern for investors. This could potentially lead to a negative sentiment around the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100